-
Blanco JC, Boukhvalova MS, Pletneva LM, Shirey KA, Vogel SN, 2014: A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology[J]. Vaccine, 32, 1495-1500. doi: 10.1016/j.vaccine.2013.11.032
-
Bouillier C, Rincheval V, Sitterlin D, Blouquit-Laye S, Desquesnes A, Eleouet JF, Gault E, Rameix-Welti MA, 2019: Generation, amplification, and titration of recombinant respiratory syncytial viruses[J]. J Vis Exp, , -. doi: 10.3791/59218
-
Bukreyev A, Belyakov IM, Berzofsky JA, Murphy BR, Collins PL, 2001: Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells[J]. J Virol, 75, 12128-12140. doi: 10.1128/JVI.75.24.12128-12140.2001
-
Bukreyev A, Whitehead SS, Murphy BR, Collins PL, 1997: Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse[J]. J Virol, 71, 8973-8982. doi: 10.1128/jvi.71.12.8973-8982.1997
-
Byrd LG, Prince GA, 1997: Animal models of respiratory syncytial virus infection[J]. Clin Infect Dis, 25, 1363-1368. doi: 10.1086/516152
-
Collins PL, Bermingham A, 1999: The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription[J]. Proc Natl Acad Sci USA, 96, 11259-11264. doi: 10.1073/pnas.96.20.11259
-
Connors M, Crowe JE, Murphy BR, Firestone CY, Collins PL, 1995: A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes[J]. Virology, 208, 478-484. doi: 10.1006/viro.1995.1178
-
Crowe JE Jr, Bui PT, Davis AR, Chanock RM, Murphy BR, 1994a: A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees[J]. Vaccine, 12, 783-790. doi: 10.1016/0264-410X(94)90286-0
-
Crowe JE Jr, Bui PT, London WT, Davis AR, Hung PP, Chanock RM, Murphy BR, 1994b: Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis[J]. Vaccine, 12, 691-699. doi: 10.1016/0264-410X(94)90218-6
-
Crowe JE Jr, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR, 1995: Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization[J]. Vaccine, 13, 847-855. doi: 10.1016/0264-410X(94)00074-W
-
Crowe JE Jr, Collins PL, London WT, Chanock RM, Murphy BR, 1993: A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV[J]. Vaccine, 11, 1395-1404. doi: 10.1016/0264-410X(93)90168-W
-
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE, 2005: Respiratory syncytial virus infection in elderly and high-risk adults[J]. N Engl J Med, 352, 1749-1759. doi: 10.1056/NEJMoa043951
-
Firestone CY, Whitehead SS, Collins PL, Murphy BR, Crowe JE Jr, 1996: Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate[J]. Virology, 225, 419-422. doi: 10.1006/viro.1996.0618
-
Fu YH, He JS, Qiao W, Jiao YY, Hua Y, Zhang Y, Peng XL, Hong T, 2013: Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice[J]. Virol J, 10, 183-. doi: 10.1186/1743-422X-10-183
-
Fu YH, Jiao YY, He JS, Giang GY, Zhang W, Yan YF, Ma Y, Hua Y, Zhang Y, Peng XL, Shi CX, Hong T, 2014: Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice[J]. Antiviral Res, 105, 72-79. doi: 10.1016/j.antiviral.2014.02.003
-
Hu B, Jiang J, Zhan J, Li G, Jiang Y, Guan X, Chen Y, Fang Z, 2014: Development of a reverse genetics system for respiratory syncytial virus long strain and an immunogenicity study of the recombinant virus[J]. Virol J, 11, 142-. doi: 10.1186/1743-422X-11-142
-
Huang Y, Cyr SL, Burt DS, Anderson R, 2009: Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine[J]. J Clin Virol, 44, 287-291. doi: 10.1016/j.jcv.2009.01.009
-
Jiao YY, Fu YH, Yan YF, Hua Y, Ma Y, Zhang XJ, Song JD, Peng XL, Huang J, Hong T, He JS, 2017: A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus[J]. Antiviral Res, 144, 57-69. doi: 10.1016/j.antiviral.2017.05.005
-
Johnson PR, Spriggs MK, Olmsted RA, Collins PL, 1987: The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins[J]. Proc Natl Acad Sci USA, 84, 5625-5629. doi: 10.1073/pnas.84.16.5625
-
Jorquera PA, Anderson L, Tripp RA, 2016: Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis[J]. Expert Rev Vaccines, 15, 173-187. doi: 10.1586/14760584.2016.1115353
-
Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE, 1969: An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine[J]. Am J Epidemiol, 89, 405-421. doi: 10.1093/oxfordjournals.aje.a120954
-
Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL, 2005: Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants[J]. J Infect Dis, 191, 1093-1104. doi: 10.1086/427813
-
Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH, 1969: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine[J]. Am J Epidemiol, 89, 422-434. doi: 10.1093/oxfordjournals.aje.a120955
-
Kohlmann R, Schwannecke S, Tippler B, Ternette N, Temchura VV, Tenbusch M, Uberla K, Grunwald T, 2009: Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus[J]. J Virol, 83, 12601-12610. doi: 10.1128/JVI.01036-09
-
Kwanten LC, De Clerck B, Roymans D (2013) A fluorescence-based high-throughput antiviral compound screening assay against respiratory syncytial virus. In: Gong EY (ed) Antiviral methods and protocols, methods in molecular biology, vol 1030. Springer Science, Berlin, pp 337-344
-
Lawlor HA, Schickli JH, Tang RS, 2013: A single amino acid in the F2 subunit of respiratory syncytial virus fusion protein alters growth and fusogenicity[J]. J Gen Virol, 94, 2627-2635. doi: 10.1099/vir.0.055368-0
-
Lin YH, Deatly AM, Chen W, Miller LZ, Lerch R, Sidhu MS, Udem SA, Randolph VB, 2006: Genetic stability determinants of temperature sensitive, live attenuated respiratory syncytial virus vaccine candidates[J]. Virus Res, 115, 9-15. doi: 10.1016/j.virusres.2005.06.013
-
Luongo C, Winter CC, Collins PL, Buchholz UJ, 2013: Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature[J]. J Virol, 87, 1985-1996. doi: 10.1128/JVI.02769-12
-
Ma Y, Jiao YY, Yu YZ, Jiang N, Hua Y, Zhang XJ, Fu YH, Peng XL, Zheng YP, Anderson LJ, He JS, 2018: A built-in CpG adjuvant in RSV F protein DNA vaccine drives a Th1 polarized and enhanced protective immune response[J]. Viruses, 10, 38-. doi: 10.3390/v10010038
-
Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, Terron MC, Melero JA, Palomo C, 2012: Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention[J]. Proc Natl Acad Sci USA, 109, 3089-3094. doi: 10.1073/pnas.1115941109
-
McFarland EJ, Karron RA, Muresan P, Cunningham CK, Libous J, Perlowski C, Thumar B, Gnanashanmugam D, Moye J, Schappell E, Barr E, Rexroad V, Fearn L, Spector SA, Aziz M, Cielo M, Beneri C, Wiznia A, Luongo C, Collins P, Buchholz UJ, 2020a: Live respiratory syncytial virus attenuated by m2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children[J]. J Infect Dis, 221, 534-543. doi: 10.1093/infdis/jiz603
-
McFarland EJ, Karron RA, Muresan P, Cunningham CK, Perlowski C, Libous J, Oliva J, Jean-Philippe P, Moye J, Schappell E, Barr E, Rexroad V, Fearn L, Cielo M, Wiznia A, Deville JG, Yang L, Luongo C, Collins PL, Buchholz UJ, 2020b: Live-attenuated respiratory syncytial virus vaccine with m2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children[J]. J Infect Dis, 221, 2050-2059. doi: 10.1093/infdis/jiaa049
-
McFarland EJ, Karron RA, Muresan P, Cunningham CK, Valentine ME, Perlowski C, Thumar B, Gnanashanmugam D, Siberry GK, Schappell E, Barr E, Rexroad V, Yogev R, Spector SA, Aziz M, Patel N, Cielo M, Luongo C, Collins PL, Buchholz UJ, International Maternal Pediatric Adolescent ACTST, 2018: Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children[J]. J Infect Dis, 217, 1347-1355. doi: 10.1093/infdis/jiy040
-
PERCH G, 2019: Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study[J]. Lancet, 394, 757-779. doi: 10.1016/S0140-6736(19)30721-4
-
Peret TC, Hall CB, Schnabel KC, Golub JA, Anderson LJ, 1998: Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community[J]. J Gen Virol, 79, 2221-2229. doi: 10.1099/0022-1317-79-9-2221
-
Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM, 1978: The pathogenesis of respiratory syncytial virus infection in cotton rats[J]. Am J Pathol, 93, 771-791.
-
Prince GA, Prieels JP, Slaoui M, Porter DD, 1999: Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus)[J]. Lab Invest, 79, 1385-1392.
-
Rostad CA, Stobart CC, Gilbert BE, Pickles RJ, Hotard AL, Meng J, Blanco JCG, Moin SM, Graham BS, Piedra PA, Moore ML, 2016: A recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein is immunogenic and protective against challenge in cotton rats[J]. J Virol, 90, 7508-7518. doi: 10.1128/JVI.00012-16
-
Schickli JH, Kaur J, Tang RS, 2012: Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030DeltaSH) at permissive and non-permissive temperatures[J]. Virus Res, 169, 38-47. doi: 10.1016/j.virusres.2012.06.027
-
Singh SR, Dennis VA, Carter CL, Pillai SR, Jefferson A, Sahi SV, Moore EG, 2007: Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model[J]. Vaccine, 25, 6211-6223. doi: 10.1016/j.vaccine.2007.05.068
-
Taylor G, 2017: Animal models of respiratory syncytial virus infection[J]. Vaccine, 35, 469-480. doi: 10.1016/j.vaccine.2016.11.054
-
Teng MN, Mejias A, Ramilo O, Peeples ME, 2020: Live attenuated vaccine with a stabilized mutation and gene deletion for prevention of respiratory syncytial virus disease in young children[J]. J Infect Dis, 221, 501-503. doi: 10.1093/infdis/jiz604
-
Troeger C, Blacker B, Khalil IA, Rao PC, Cao J, Zimsen SRM, Albertson SB, Deshpande A, Farag T, Abebe Z, 2018: Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Infect Dis, 18, 1191-1210. doi: 10.1016/S1473-3099(18)30310-4
-
van Elden LJ, van Loon AM, van der Beek A, Hendriksen KA, Hoepelman AI, van Kraaij MG, Schipper P, Nijhuis M, 2003: Applicability of a real-time quantitative PCR assay for diagnosis of respiratory syncytial virus infection in immunocompromised adults[J]. J Clin Microbiol, 41, 4378-4381. doi: 10.1128/JCM.41.9.4378-4381.2003
-
Whitehead SS, Bukreyev A, Teng MN, Firestone CY, St Claire M, Elkins WR, Collins PL, Murphy BR, 1999: Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees[J]. J Virol, 73, 3438-3442. doi: 10.1128/JVI.73.4.3438-3442.1999
-
Whitehead SS, Firestone CY, Collins PL, Murphy BR, 1998a: A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes[J]. Virology, 247, 232-239. doi: 10.1006/viro.1998.9248
-
Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR, 1998b: Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees[J]. J Virol, 72, 4467-4471. doi: 10.1128/JVI.72.5.4467-4471.1998
-
Wright PF, Karron RA, Belshe RB, Thompson J, Crowe Jr JE, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR, 2000: Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy[J]. J Infect Dis, 182, 1331-1342. doi: 10.1086/315859
-
Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, O'Shea AF, Gruber WC, Murphy BR, 2007: The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines[J]. Vaccine, 25, 7372-7378. doi: 10.1016/j.vaccine.2007.08.014
-
Xu M, Jiao YY, Fu YH, Jiang N, Zheng YB, Yan YF, Zhang M, Zheng YP, Zhu WY, Peng XL, He JS, 2018: Construction and characterization of a recombinant human respiratory syncytial virus encoding enhanced green fluorescence protein for antiviral drug screening assay[J]. Biomed Res Int, 2018, 8431243-.